Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment

Summary

This is a single arm study with axitinib in patients with advanced kidney cancer (clear cell variant), who have failed first line therapy. The study will recruit a maximum of 30 patients from 2 countries including Australia and Canada. Patients will be followed up for efficacy, safety and health related outcomes.

Timeline

Start

2012-03

Primary completion

2014-03

Completion

2014-03

Drugs

Indications